Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY: BSX )

90.00 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Boston Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stryker Stock Sees Relative Strength Rating Jump To 84
The Relative Strength (RS) Rating for Stryker stock jumped into a new percentile Thursday, with a rise from 76 to 84. 
Via Investor's Business Daily
AT&T To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Key Takeaways From Boston Scientific Analyst Ratings
Via Benzinga
Biotech And Medtech Portfolio Notes On A Fed Day
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23% 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Nasdaq, S&P 500 Slip Ahead Of Fed Meeting, Regional Banks Sink After NYCB Disappoints: What's Driving Markets Wednesday?
Nasdaq down 1.4%, S&P 500 down 0.9%, Dow up: Volatile day on Wall Street as tech stocks react to disappointing earnings ahead of Fed meeting. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Medical Devices Giant Boston Scientific Shares Are Rising Today
Boston Scientific shares surge in premarket trading following strong Q4 results, beating revenue estimates, amid positive outlook for 2024. 
Via Benzinga
Boston Scientific Surges On Its 'Impressive' First-Quarter Guidance
The company expects sales to grow 7% to 9% organically, above expectations. 
Via Investor's Business Daily
Stryker, Boston Scientific Score Earnings Beats, Extend Breakouts
Shares of Stryker, Boston Scientific jumped early Wednesday after healthy earnings beats and price target hikes from analysts. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Preview: Boston Scientific's Earnings
Via Benzinga
Looking Into Boston Scientific's Recent Short Interest
Via Benzinga
Demystifying Boston Scientific: Insights From 10 Analyst Reviews
Via Benzinga
Earnings Scheduled For January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
Why Axonics Stock Soared Today
The medical device maker agreed to be acquired by Boston Scientific. 
Via The Motley Fool
Boston Scientific Corporation Should Continue Uptrend & Remain Supported
Boston Scientific Corporation develops, manufactures & markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg & Cardiovascular segments. 
Via Talk Markets
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Health Care Company Boston Scientific Announces Acquisition of Axonics
Via Benzinga
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth. 
Via Benzinga
Chart Of The Day: Boston Scientific - Revenue Growth Potential
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. 
Via Talk Markets
Palo Alto Networks, Nvidia, And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed slightly lower on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
7 Healthcare Stocks Taking Medicine to the Next Level
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
Via InvestorPlace
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
5 A-Rated Stocks to Buy ASAP in 2024
2024 is ushering in a new era for investors, and these top-notch, A-rated stocks to buy are likely to be market winners. Here's why. 
Via InvestorPlace
10 Top Stocks With a Strong Buy Rating Right Now
Wall Street is highly bullish on these strong buy stocks, even as financial markets face an uncertain year. Here are the names to watch. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Is Axonics (AXNX) Stock Up 20% Today?
Axonics stock is rising higher on Monday as investors react to a $71 per share cash offer for AXNX stock from Boston Scientific. 
Via InvestorPlace
Why Is Bladder Disorder Focused Axonics Stock Trading Higher Today?
Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $7 
Via Benzinga
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
The year's biggest medical conference kicked off with a melee of buyout news. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.